Creative Biolabs has announced a significant expansion of its advanced single-cell multi-omics and RNA sequencing solutions, aiming to meet the growing demand for high-resolution cellular profiling in biomedical discovery. The upgraded suite provides end-to-end services that span single-cell transcriptome profiling to integrated multimodal and multi-omics workflows, supporting researchers in oncology, immunology, and neuroscience. This development matters because it addresses a critical bottleneck in life science research: the need to dissect cellular heterogeneity at single-cell resolution to identify rare cell subpopulations, characterize complex tumor microenvironments, and trace cell lineage trajectories.
As research increasingly moves from bulk tissue profiling to single-cell analysis, the ability to process challenging samples has become paramount. Creative Biolabs now offers robust, high-throughput single-cell RNA sequencing services that deliver high sensitivity and coverage across thousands of individual cells. These services enable high-resolution transcriptomic insights from diverse fresh biological specimens, which is essential for understanding disease mechanisms and developing targeted therapies.
A key innovation is the platform's specialized single-nucleus RNA sequencing (snRNA-seq) capabilities. Traditional single-cell dissociation can damage cells, induce stress responses, or lead to selective loss of fragile cell types—particularly in tissues like human brain, myocardium, or flash-frozen clinical biopsies. Creative Biolabs addresses this with an optimized single-cell nuclei RNA sequencing service that isolates intact nuclei, bypassing harsh enzymatic dissociation and minimizing artifacts while retaining informative nuclear RNA profiles. This dramatically expands the scope of clinical translational research, allowing scientists to analyze archival and difficult-to-process samples that were previously inaccessible.
Beyond single-dimensional analysis, Creative Biolabs has advanced its high-throughput single-cell multi-omics service, which simultaneously interrogates genomic variations, epigenomic landscapes (such as chromatin accessibility), cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By linking epigenetic regulation and genomic alterations directly to gene expression readouts, this integrated platform empowers researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented clarity. The implications for precision medicine and biomarker discovery are profound, as understanding biology at single-cell and single-nucleus resolution becomes fundamental to developing effective treatments.
“Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery,” said a senior scientist at Creative Biolabs. “Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support.” This commitment is backed by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines.
The expansion positions Creative Biolabs as a key partner for academic and biopharmaceutical research teams worldwide. By enabling comprehensive single-cell analysis, the company supports discovery programs in target validation, immunology profiling, and translational drug development. As the life sciences continue to embrace single-cell resolution, such integrated solutions will be instrumental in unraveling the complexities of human disease and accelerating the pace of biomedical innovation.
